Over the last 7 days, the United States market has experienced a decline of 4.1%, yet it has shown resilience with a 6.6% increase over the past year, and earnings are anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation despite short-term market fluctuations.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
TG Therapeutics | 26.18% | 37.61% | ★★★★★★ |
Alkami Technology | 20.45% | 85.16% | ★★★★★★ |
Travere Therapeutics | 28.43% | 65.01% | ★★★★★★ |
AVITA Medical | 27.78% | 55.33% | ★★★★★★ |
Clene | 61.16% | 59.11% | ★★★★★★ |
Alnylam Pharmaceuticals | 22.82% | 58.64% | ★★★★★★ |
Blueprint Medicines | 22.49% | 55.91% | ★★★★★★ |
TKO Group Holdings | 22.54% | 25.17% | ★★★★★★ |
Alvotech | 31.17% | 100.18% | ★★★★★★ |
Lumentum Holdings | 21.55% | 119.67% | ★★★★★★ |
Click here to see the full list of 243 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Natera, Inc. is a diagnostics company that provides molecular testing services globally, with a market capitalization of approximately $19.53 billion.
Operations: The company generates revenue primarily through the development and commercialization of molecular testing services, amounting to approximately $1.70 billion.
Natera, a player in the genetic testing and diagnostics sector, is navigating a path toward profitability with an expected annual profit growth of 54.11%, outpacing its industry's average. Despite current unprofitability, its strategic R&D investment, which aligns with its revenue growth at 13% annually, underscores a commitment to innovation in oncology and prenatal testing fields. Recent board expansions and clinical trials like HEROES indicate proactive governance and research depth. With a forecasted revenue upswing to $1.95 billion by year-end 2025 amidst robust earnings projections, Natera is positioning itself as a pivotal figure in biotech's evolution driven by precision medicine advancements.
Review our historical performance report to gain insights into Natera's's past performance.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Corning Incorporated operates in optical communications, display technologies, environmental technologies, specialty materials, and life sciences sectors both in the United States and internationally, with a market capitalization of approximately $38.89 billion.
Operations: Corning generates revenue across several segments, with Optical Communications and Display Technologies being the largest contributors at $4.66 billion and $3.87 billion, respectively. Specialty Materials also plays a significant role with $2.02 billion in revenue, while Environmental Technologies and Life Sciences contribute $1.67 billion and $979 million, respectively.
Corning, a key innovator in materials science, is rapidly advancing in high-tech sectors through strategic R&D and partnerships. With an annualized revenue growth of 9.5% and earnings growth at 39.6%, the company demonstrates robust financial health amidst challenging market conditions. Recent collaborations, like supplying wafers and polysilicon for U.S.-made solar modules, underscore its commitment to domestic manufacturing and sustainability. This initiative not only leverages Corning's material science expertise but also aligns with increasing demand for renewable energy solutions, potentially boosting future revenues while supporting the industry's shift towards more sustainable practices.
Assess Corning's past performance with our detailed historical performance reports.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Phreesia, Inc. offers an integrated SaaS-based software and payment platform tailored for the healthcare sector in the United States and Canada, with a market capitalization of $1.40 billion.
Operations: The company generates revenue primarily from its healthcare software segment, which accounted for $419.81 million. The platform is designed to streamline operations in the healthcare sector across the United States and Canada.
Phreesia, navigating the competitive landscape of healthcare technology, has demonstrated a notable turnaround in its financial health. With a substantial reduction in net loss from $136.89 million to $58.53 million year-over-year and an increase in annual revenue by 17.8% to $419.81 million, the company is on a path to profitability, expected within three years. This growth trajectory is supported by strategic initiatives like the recent shelf registration aimed at raising nearly $70 million, potentially fueling further innovations and market expansion. Despite current unprofitability, Phreesia's aggressive investment in R&D and market strategies positions it as an emerging contender with promising prospects for growth exceeding industry averages.
Gain insights into Phreesia's past trends and performance with our Past report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:NTRA NYSE:GLW and NYSE:PHR.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.